Quarterly Results Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Net Sales
0.82
1.12
1.30
1.26
1.11
1.26
1.28
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
0.82
1.12
1.30
1.26
1.11
1.26
1.28
Raw Material Cost
0.79
0.87
0.86
1.22
0.78
0.92
1.23
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.02
0.00
0.35
0.00
0.00
Selling and Distribution Expenses
1.52
1.43
2.17
1.25
1.48
1.33
1.12
Other Expenses
0.06
0.06
0.01
0.09
0.07
0.08
0.12
Total Expenditure (Excl Depreciation)
2.94
2.88
3.15
3.38
3.32
3.02
3.56
Operating Profit (PBDIT) excl Other Income
-2.1
-1.7999999999999998
-1.7999999999999998
-2.1
-2.2
-1.7999999999999998
-2.3000000000000003
Other Income
0.09
0.04
0.07
-0.01
-0.02
0.08
0.08
Operating Profit (PBDIT)
-1.87
-1.57
-1.64
-1.99
-2.09
-1.53
-2.04
Interest
0.00
0.00
0.02
0.00
0.35
0.00
0.00
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
0.03
0.25
0.45
0.05
0.33
0.35
0.05
Depreciation
0.16
0.16
0.13
0.13
0.13
0.14
0.15
Profit Before Tax
-2.03
-1.73
-1.79
-2.12
-2.58
-1.68
-1.93
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.01
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
-2.03
-1.73
-1.79
-2.12
-2.58
-1.68
-1.94
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
-2.03
-1.73
-1.79
-2.12
-2.58
-1.68
-1.94
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
-2.03
-1.73
-1.79
-2.12
-2.58
-1.68
-1.94
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
9.59
11.59
13.43
7.02
6.18
8.40
9.21
Earnings per share (EPS)
-0.51
-0.44
-0.89
-1.94
-3.64
-2.71
-4.34
Diluted Earnings per share
-0.51
-0.44
-0.89
-1.94
-3.64
-2.71
-4.34
Operating Profit Margin (Excl OI)
-258.57%
-157.45%
-141.19%
-167.67%
-198.46%
-138.72%
-177.11%
Gross Profit Margin
-228.02%
-140.18%
-127.02%
-157.85%
-219.85%
-121.21%
-138.63%
PAT Margin
-247.29%
-154.17%
-137.07%
-168.12%
-231.63%
-132.68%
-151.02%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Dec 2025 is -27.27% vs -8.33% in Dec 2024
Consolidate Net Profit
YoY Growth in quarter ended Dec 2025 is 23.08% vs -73.33% in Dec 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Dec 2025 is 4.76% vs -31.25% in Dec 2024
Interest
YoY Growth in quarter ended Dec 2025 is -100.00% vs 0.00% in Dec 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Dec 2025 has fallen from Dec 2024
Compare Quarterly Results Of InMed Pharmaceuticals, Inc. With
Figures in Million
Consolidate Quarterly Results
Change(USD)
Change(%)
Net Sales
0.82
0.06
0.76
1,266.67%
Other Operating Income
0.00
0.00
0.00
Total Operating income
0.82
0.06
0.76
1,266.67%
Raw Material Cost
0.79
0.02
0.77
3,850.00%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
8.60
-8.60
-100.00%
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
1.52
6.52
-5.00
-76.69%
Other Expenses
0.06
0.47
-0.41
-87.23%
Total Expenditure (Excl Depreciation)
2.94
19.80
-16.86
-85.15%
Operating Profit (PBDIT) excl Other Income
-2.12
-19.74
17.62
89.26%
Other Income
0.09
0.99
-0.90
-90.91%
Operating Profit (PBDIT)
-1.87
-18.73
16.86
90.02%
Interest
0.00
0.00
0.00
Exceptional Items
0.00
5.16
-5.16
-100.00%
Gross Profit (PBDT)
0.03
0.04
-0.01
-25.00%
Depreciation
0.16
0.02
0.14
700.00%
Profit Before Tax
-2.03
-13.59
11.56
85.06%
Tax
0.00
0.13
-0.13
-100.00%
Provisions and contingencies
0
0
0.00
Profit After Tax
-2.03
-13.72
11.69
85.20%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
-2.03
-13.72
11.69
85.20%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
-2.03
-13.72
11.69
85.20%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
9.59
83.05
-73.46
-88.45%
Earnings per share (EPS)
-0.51
-0.74
0.23
31.08%
Diluted Earnings per share
-0.51
-0.74
0.23
31.08%
Operating Profit Margin (Excl OI)
-258.57%
-33,461.02%
0.00
33,202.45%
Gross Profit Margin
-228.02%
-23,006.78%
0.00
22,778.76%
PAT Margin
-247.29%
-23,254.24%
0.00
23,006.95%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 0.08 Million
in Dec 2025Figures in Million
QoQ Growth in quarter ended Dec 2025 is -27.27% vs -15.38% in Sep 2025
YoY Growth in quarter ended Dec 2025 is -27.27% vs -8.33% in Dec 2024
Quarterly - Consolidate Net Profit
Consolidate Net Profit -0.20 Million
in Dec 2025Figures in Million
QoQ Growth in quarter ended Dec 2025 is -17.65% vs 5.56% in Sep 2025
YoY Growth in quarter ended Dec 2025 is 23.08% vs -73.33% in Dec 2024
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -0.20 Million
in Dec 2025Figures in Million
QoQ Growth in quarter ended Dec 2025 is -25.00% vs 5.88% in Sep 2025
YoY Growth in quarter ended Dec 2025 is 4.76% vs -31.25% in Dec 2024
Quarterly - Interest
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -258.57%
in Dec 2025Figures in %
QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025
YoY Growth in quarter ended Dec 2025 has fallen from Dec 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
